Two biotech firms are trying to cash in on investor excitement around obesity drugs and disease-detecting technology. One company wants $533 million to develop weight-loss treatments, while another seeks $159 million to expand its diagnostic tools. Both plan to sell shares to the public soon, hoping
After someone with Bipolar II disorder is hospitalized for the first time, their risk of attempting suicide doesn’t disappear—it actually spikes. New research shows that the months right after discharge are some of the most dangerous periods for these patients. Scientists tracked a group of Bipolar
A new approach turns a common antioxidant into a multitasking enhancer for inverted perovskite solar cells, tackling the long‑standing clash between power output and longevity. The trick lies in adding reduced glutathione (GSH) to the device’s thin‑film layers. GSH acts on several levels: it creates
When people talk about SpaceX’s upcoming stock market debut, they usually focus on two things: how the company launches rockets and its rapidly growing Starlink internet service. But one investor suggests Wall Street is looking at the wrong details entirely. Gene Munster, a well-known financial anal
A key financial leader has left xAI, the AI startup connected to SpaceX. The former CFO, Anthony Armstrong, stepped down recently. His departure comes as other top executives also exit, showing bigger changes inside the company. Armstrong had a big role before—helping with the purchase of X (formerl
Gordon has spent years pushing academic discussions forward. Not by avoiding tough topics but by diving right into them. He doesn’t just present ideas—he tests them, challenges them, and makes sure they hold up under scrutiny. That approach has shaped how experts view mood disorders, especially bipo
The last of the original team that helped Elon Musk launch xAI has left, a move that comes as the company readies for a major change in its structure. Ross Nordeen, who had been Musk’s right‑hand man and handled day‑to‑day priorities, stepped away this week. He is no longer listed on the company’s X
Children who grow up with Congenital Adrenal Hyperplasia (CAH) caused by a 21‑hydroxylase enzyme problem often show changes in body weight that differ from their peers. Scientists track a key moment called adiposity rebound, when the body mass index (BMI) stops falling and begins to climb again a
Delton Technology (Guangzhou) plans to raise up to $423 million by selling 46 million H‑shares in Hong Kong. The maximum price per share is set at HK$71. 88, according to the company’s filing. The final pricing will be announced on March 19 and trading will start the next day. The move comes as a w
Vincorion, a German company that builds advanced defense equipment, is preparing to launch its first public offering in Frankfurt this week. This move comes even as global stock markets feel the strain from ongoing conflicts in the Middle East. Investors see a bright future for Vincorion because of
